• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Comparative Effectiveness of Bisoprolol, Carvedilol, and Metoprolol Succinate in Patients with Heart Failure and CKD.

作者信息

Huang Cheng-Wei, Yu Albert S, Zhou Hui, Pak Katherine, Shaw Sally F, Shi Jiaxiao, Broder Benjamin I, Sim John J

机构信息

Department of Hospital Medicine, Kaiser Permanente Los Angeles Medical Center, Los Angeles, California.

Kaiser Permanente Bernard J. Tyson School of Medicine, Pasadena, California.

出版信息

Clin J Am Soc Nephrol. 2025 Jan 1;20(1):136-138. doi: 10.2215/CJN.0000000000000562. Epub 2024 Sep 6.

DOI:10.2215/CJN.0000000000000562
PMID:39792541
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11737438/
Abstract
摘要

相似文献

1
Comparative Effectiveness of Bisoprolol, Carvedilol, and Metoprolol Succinate in Patients with Heart Failure and CKD.比索洛尔、卡维地洛和琥珀酸美托洛尔在心力衰竭合并慢性肾脏病患者中的疗效比较
Clin J Am Soc Nephrol. 2025 Jan 1;20(1):136-138. doi: 10.2215/CJN.0000000000000562. Epub 2024 Sep 6.
2
Bisoprolol compared with carvedilol and metoprolol succinate in the treatment of patients with chronic heart failure.比索洛尔与卡维地洛和琥珀酸美托洛尔治疗慢性心力衰竭患者的比较。
Clin Res Cardiol. 2017 Sep;106(9):711-721. doi: 10.1007/s00392-017-1115-0. Epub 2017 Apr 22.
3
Differences between beta-blockers in patients with chronic heart failure and chronic obstructive pulmonary disease: a randomized crossover trial.β受体阻滞剂在慢性心力衰竭和慢性阻塞性肺疾病患者中的差异：一项随机交叉试验。
J Am Coll Cardiol. 2010 Apr 27;55(17):1780-7. doi: 10.1016/j.jacc.2010.01.024.
4
[Congestive heart failure in Spain: cost-effectiveness and cost-benefit analyses of treatment with beta-blockers].[西班牙的充血性心力衰竭：β受体阻滞剂治疗的成本效益和成本效益分析]
Rev Clin Esp. 2005 Apr;205(4):149-56. doi: 10.1157/13074160.
5
Which should you choose for post operative atrial fibrillation, carvedilol or metoprolol? A systemic review and meta-analysis.术后心房颤动，你应该选择卡维地洛还是美托洛尔？一项系统评价和荟萃分析。
Curr Probl Cardiol. 2024 Feb;49(2):102220. doi: 10.1016/j.cpcardiol.2023.102220. Epub 2023 Nov 19.
6
Older adults with heart failure treated with carvedilol, bisoprolol, or metoprolol tartrate: risk of mortality.接受卡维地洛、比索洛尔或酒石酸美托洛尔治疗的老年心力衰竭患者：死亡风险
Pharmacoepidemiol Drug Saf. 2017 Jan;26(1):81-90. doi: 10.1002/pds.4132. Epub 2016 Nov 16.
7
Effectiveness and safety of four different beta-blockers in patients with chronic heart failure.四种不同β受体阻滞剂对慢性心力衰竭患者的有效性和安全性
MedComm (2020). 2023 Jan 6;4(1):e199. doi: 10.1002/mco2.199. eCollection 2023 Feb.
8
Patterns of beta-blocker use and dose optimization among ambulatory heart failure patients with reduced ejection fraction (HFrEF) attending public hospitals in Northeast Ethiopia: a multi-center cross-sectional study.埃塞俄比亚东北部公立医院门诊射血分数降低的心力衰竭（HFrEF）患者中β受体阻滞剂的使用模式及剂量优化：一项多中心横断面研究
BMC Cardiovasc Disord. 2025 Jan 23;25(1):43. doi: 10.1186/s12872-025-04501-5.
9
Metabolomics of repetitive myocardial stunning in chronic multivessel coronary artery stenosis: Effect of non-selective and selective β1-receptor blockers.慢性多支冠状动脉狭窄复发性心肌顿抑的代谢组学：非选择性和选择性β1-受体阻滞剂的影响。
J Physiol. 2024 Jul;602(14):3423-3448. doi: 10.1113/JP285720. Epub 2024 Jun 17.
10
In heart failure, all beta-blockers are not necessarily equal.在心力衰竭中，并非所有的β受体阻滞剂都一样。
Cleve Clin J Med. 2003 Dec;70(12):1081-7. doi: 10.3949/ccjm.70.12.1081.

本文引用的文献

1
All-Cause and Cardiovascular-Related Mortality in CKD Patients With and Without Heart Failure: A Population-Based Cohort Study in Kaiser Permanente Southern California.患有和未患有心力衰竭的慢性肾脏病患者的全因死亡率和心血管相关死亡率：南加州凯撒医疗机构基于人群的队列研究
Kidney Med. 2023 Mar 9;5(5):100624. doi: 10.1016/j.xkme.2023.100624. eCollection 2023 May.
2
2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines.2022年美国心脏协会/美国心脏病学会/美国心力衰竭学会心力衰竭管理指南：美国心脏病学会/美国心脏协会临床实践指南联合委员会报告
Circulation. 2022 May 3;145(18):e895-e1032. doi: 10.1161/CIR.0000000000001063. Epub 2022 Apr 1.
3
Comparative effectiveness of bisoprolol and carvedilol among patients receiving maintenance hemodialysis.比索洛尔与卡维地洛在维持性血液透析患者中的疗效比较。
Clin Kidney J. 2021 Jan 4;14(3):983-990. doi: 10.1093/ckj/sfaa248. eCollection 2021 Mar.
4
β-Blocker Use and Risk of Mortality in Heart Failure Patients Initiating Maintenance Dialysis.β受体阻滞剂在开始维持性透析的心力衰竭患者中的使用与死亡率的关系。
Am J Kidney Dis. 2021 May;77(5):704-712. doi: 10.1053/j.ajkd.2020.07.023. Epub 2020 Nov 15.
5
A Comparative Study of Carvedilol Versus Metoprolol Initiation and 1-Year Mortality Among Individuals Receiving Maintenance Hemodialysis.卡维地洛与美托洛尔起始治疗对维持性血液透析患者 1 年死亡率的比较研究。
Am J Kidney Dis. 2018 Sep;72(3):337-348. doi: 10.1053/j.ajkd.2018.02.350. Epub 2018 Apr 10.
6
Disparities in early mortality among chronic kidney disease patients who transition to peritoneal dialysis and hemodialysis with and without catheters.慢性肾脏病患者在转为腹膜透析和血液透析时，无论是否使用导管，早期死亡率存在差异。
Int Urol Nephrol. 2018 May;50(5):963-971. doi: 10.1007/s11255-018-1837-6. Epub 2018 Mar 12.